Detection Of Plasma DNA Methylation In Peripheral Blood From Patients With Hepatocellular Carcinoma

Overview

About this study

This study aims to investigate the utility of using plasma DNA methylation to detect measurable residual disease or early recurrence/progression of patients with hepatocellular carcinoma.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

Adult, age ≥18.
Patients scheduled for resection for hepatocellular carcinoma.
Patients whose clinical provider orders cancer care tissue mutation profiling test for clinical care.

Exclusion Criteria:

Females who are pregnant or attempt to become pregnant.
Patent with significant anemia (Hb < 7g/dL).

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status	Contact
Rochester, Minn. Mayo Clinic principal investigator Nguyen Tran, M.D.	Closed for enrollment	Contact information: Nguyen Tran Tran.Nguyen@mayo.edu

Mayo Clinic Location

Status

Contact

Rochester, Minn.

Mayo Clinic principal investigator

Nguyen Tran, M.D.

Closed for enrollment

Contact information:

Nguyen Tran

Tran.Nguyen@mayo.edu

More information

Publications

Publications are currently not available

Clinical Trials